The Ministry of Health has withdrawn from the market products containing cyclandelate (Cyclospasmol: Ives Labs.) because they are considered to be ineffective for the stated indications (intermittent claudication caused by arteriosclerosis obliterans and as a treatment for cognitive dysfunction in patients suffering from senile dementia of the multi-infarct or Alzheimer’s type).

[See also Pharmaceuticals Newsletter Nos. 5/6, January & February 1997]

References:

1) Communication from the WHO Regional Office for the Eastern Mediterranean enclosing a notification from the Ministry of Health, Saudi Arabia, 20 June 1999.

2) Federal Register 61 (233): 64099-64136 (1996).